IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy.
Lee KJ, Choi D, Tae N, Song HW, Kang YW, Lee M, Moon D, Oh Y, Park S, Kim JH, Jeong S, Yang J, Park U, Hong DH, Byun MS, Park SH, Sohn J, Park Y, Im SK, Choi SS, Kim DH, Lee SW.
Lee KJ, et al. Among authors: song hw.
Cell Rep Med. 2024 May 7:101567. doi: 10.1016/j.xcrm.2024.101567. Online ahead of print.
Cell Rep Med. 2024.
PMID: 38744277
Free article.